Testing AI-based eye screening for diabetes complications in primary care
Tests an AI eye screening program for diabetic retinopathy in adults with diabetes.
Plain-language title generated from the registry record
Registry title: Leveraging Artificial Intelligence to Prevent Vision Loss From Diabetes
Key facts
- Where
- Madison, United StatesSee the site
Where in United States
- UW School of Medicine and Public HealthMadison, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Wisconsin, Madison
- Trial code
- NCT06763952
- Record updated
- 22 October 2026
- Original description
This pragmatic clinical trial is being conducted to test the effectiveness of AI-BRIDGE (Artificial Intelligence-Based point of caRe, Incorporating Diagnosis, SchedulinG, and Education), in improving screening and follow-up eye care compared to usual-care among patients with diabetes across 8 primary care clinics. AI-BRIDGE is an implementation program which includes an autonomous AI-based protocol that provides screening for diabetic retinopathy (DR) disease at primary care visits, as well as patient education on disease and, if a patient screens positive for referable DR or has insufficient quality image, or image unobtainable due to other technical issues, or does not get AI-screening for any reason, assistance with scheduling an in-person, follow-up eye-care visit.Read full original descriptionShow less
Multicenter National Parallel Cluster Randomized Controlled Superiority Trial Comparing an Artificial Intelligence-Based Screening Strategy to Usual Care for Improving Eye-Care Follow-Up Among Patients With Diabetes (AI-BRIDGE Trial)
This pragmatic clinical trial is being conducted to test the effectiveness of AI-BRIDGE (Artificial Intelligence-Based point of caRe, Incorporating Diagnosis, SchedulinG, and Education), in improving screening and follow-up eye care compared to usual-care among patients with diabetes across 8 primary care clinics. AI-BRIDGE is an implementation program which includes an autonomous AI-based protocol that provides screening for diabetic retinopathy (DR) disease at primary care visits, as well as patient education on disease and, if a patient screens positive for referable DR or has insufficient quality image, or image unobtainable due to other technical issues, or does not get AI-screening for any reason, assistance with scheduling an in-person, follow-up eye-care visit.
Clinics Inclusion Criteria:; Clinic must be from a health system with at least two clinics that meet eligibility criteria and will agree to join; Number of unique patients with diabetes should be >550 over any continuous 15-month period prior to the clinic providing a letter of support to participate in the trial; No point-of-care screening system in use for DR; Have an electronic health record to track patient data and agree to share limited data set as requested; Have a member of the clinical team who can commit to serving as the clinic champion for this study; Have the IT infrastructure to deploy an artificial-intelligence-based eye camera in the clinic; Patient Inclusion Criteria:; Diagnosis of type 1 or 2 diabetes; No known diabetic retinopathy; No diabetic retinopathy screening in the past 12 months; Patient Exclusion Criteria:; Have a documented DR screening in the electronic health record within 12 months of the date of the primary care visit; Contraindication includes diagnosed with macular edema, severe non-proliferative retinopathy, proliferative retinopathy, radiation retinopathy, or retinal vein occlusion; Pregnant.